About Us

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing and delivering cell and gene therapies for serious diseases with high unmet need. Abeona’s ZEVASKYN® (prademagene zamikeracel) was approved in April of 2025.

Leveraging our expertise in ex vivo gene therapy and viral vector technologies, Abeona is advancing SIR-T™ technology intended to address a significant unmet need in patients with solid tumors. Our lead asset, ABO-701, is a potentially first in class, prostate-specific membrane antigen (PSMA) targeted synthetic immune receptor T cell (SIR T™) therapy being developed for advanced prostate cancer. It applies a next generation engineered T cell technology to a clinically validated target (PSMA), in a setting with significant unmet need.

Our values drive us forward as we work to bring the promise of genetic medicine to patients and their families:

  • Patients First: From development priorities to patient support and family education programs, everything we do is centered around patient needs, clinical urgency and measurable improvements in the quality of life of those we serve.
  • Innovation: By following the leading edge of scientific discovery we strive to realize innovation at all stages of development from vector design to manufacturing scale. We are dedicated to realizing scientific opportunity to deliver life-changing medicines.
  • Integrity: Scientific rigor, quality manufacturing and ethical decision-making underpin every program and partnership we endeavor upon.
  • Determination: We pursue ambitious goals with discipline and resilience, accelerating programs with the potential to redefine standard-of-care.
  • Trust: We foster long-term trust and collaborative relationships with every stakeholder from patients, to investigators, to employees and shareholders. We build trust through transparency, consistency and accountability.

 

Learn more about our culture and values by clicking here.